Bristol-Myers Squibb (BMY) AI Stock Analysis

• Market Cap: $94.49B
• Dividend Yield: 5.34%
• Average Volume (3M): 12.74M
• Price to Earnings (P/E): 17.4
• Beta (1Y): 0.17
• Revenue Growth: 4.62%
• EPS Growth: N/A
• Country: US
• Employees: 34,100
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.80
• Shares Outstanding: 2,035,080,800
• 10 Day Avg. Volume: 10,599,101
• 30 Day Avg. Volume: 12,739,359
• PEG Ratio: 0.11
• Price to Book (P/B): 5.42
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 7.21
• Enterprise Value/Market Cap: 1.43
• Enterprise Value/Revenue: 0.71
• Enterprise Value/Gross Profit: 4.29
• Enterprise Value/Ebitda: 4.57
• 1Y Price Target: $55.40
• Price Target Upside: 17.45% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 20

• Rating: 66 Neutral
• Price Target: $50.00 ▲(6.00%Upside)

Bristol-Myers Squibb's overall stock score is primarily driven by strong financial performance and attractive valuation, bolstered by increased guidance from the recent earnings call. However, bearish technical indicators and external challenges, including regulatory pressures and clinical trial setbacks, temper the outlook.

Positive Factors

Market Expansion

BMY is working to expand the label for Cobenfy across a number of additional indications, including Alzheimer's Disease Psychosis (ADP).

Market Opportunity

There is a significant market opportunity with over 7 million patients with Alzheimer's disease in the US, and no approved therapy for Alzheimer's Disease Psychosis.

Regulatory Approval

Cobenfy is one of the company's key new product cycles, which was approved by FDA for schizophrenia.

Negative Factors

Financial Projections

Cobenfy scripts are expected to miss Visible Alpha consensus estimates for 2Q25 revenue.

Prescription Trends

Cobenfy prescriptions for schizophrenia have recently moderated, which could affect stock reaction.

Trial Outcomes

If Cobenfy fails in Alzheimer's Disease Psychosis, there is a potential downside in shares of more than 5%.

Bristol-Myers Squibb Business Overview & Revenue Model

Company Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

How the Company Makes Money

Bristol-Myers Squibb generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is centered around the development, marketing, and distribution of prescription medicines that address areas with significant unmet medical needs. Key revenue streams include its blockbuster drugs in oncology, such as Opdivo and Yervoy, which are used in cancer treatment, and Eliquis, a leading anticoagulant. Additionally, the company invests heavily in research and development to expand its pipeline of potential new medicines. Partnerships and collaborations with other pharmaceutical companies and research institutions also play a significant role in BMY's revenue generation, enhancing its capabilities in drug discovery and commercialization. Furthermore, strategic acquisitions and alliances help Bristol-Myers Squibb maintain a competitive edge in the biopharmaceutical industry.

Bristol-Myers Squibb Financial Statement Overview

Summary

Bristol-Myers Squibb demonstrates resilient financial performance with strengths in cash flow generation and gross profitability. However, net income variability and increased leverage pose potential risks. Continued focus on stabilizing earnings and managing liabilities will be crucial for sustained financial health.

Income Statement

The income statement reveals a stable performance with gross profit margins consistently strong around 70%. However, the net profit margin has fluctuated significantly, with a notable loss in 2024. Revenue growth has been stable, with a slight decline in recent periods. The EBIT and EBITDA margins are solid for the TTM, reflecting efficient cost management despite earlier fluctuations.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. The equity ratio has decreased over time, suggesting an increase in liabilities relative to assets. Return on equity has varied, impacted by fluctuating net income, with a recent improvement in profitability contributing positively.

Cash Flow

Cash flow analysis is favorable, with strong and improving free cash flow, highlighting efficient cash generation. The operating cash flow to net income ratio indicates robust cash conversion efficiency, although historical net income volatility presents some risk. Free cash flow growth is positive, supporting a strong cash position.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	48.30B	45.01B	46.16B	46.38B	42.52B
Gross Profit	34.33B	34.31B	36.02B	36.45B	30.75B
EBITDA	3.22B	19.42B	19.23B	20.19B	5.04B
Net Income	-8.95B	8.03B	6.33B	6.99B	-8.99B
Balance Sheet
Total Assets	92.60B	95.16B	96.82B	109.31B	118.48B
Cash, Cash Equivalents and Short-Term Investments	10.86B	12.28B	9.12B	13.98B	14.55B
Total Debt	51.20B	41.46B	40.72B	45.60B	51.67B
Total Liabilities	76.22B	65.67B	65.70B	73.31B	80.60B
Stockholders Equity	16.34B	29.43B	31.06B	35.95B	37.82B
Cash Flow
Free Cash Flow	13.94B	12.65B	11.95B	15.23B	13.30B
Operating Cash Flow	15.19B	13.86B	13.07B	16.21B	14.05B
Investing Cash Flow	-21.35B	-2.29B	-1.06B	-538.00M	-10.86B
Financing Cash Flow	5.13B	-9.42B	-16.96B	-16.22B	-1.15B

Bristol-Myers Squibb Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 47.17
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMY, the sentiment is Neutral. The current price of 47.17 is above the 20-day moving average (MA) of 46.69, above the 50-day MA of 47.01, and below the 200-day MA of 52.66, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 50.15 is Neutral, neither overbought nor oversold. The STOCH value of 32.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMY.

Bristol-Myers Squibb Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRK	81 Outperform	$210.10B	12.18	39.31%	3.97%	4.40%	654.93%
PFE	72 Outperform	$144.12B	18.37	8.62%	6.99%	13.38%	―
GILD	71 Outperform	$139.43B	23.57	32.51%	2.90%	4.63%	1144.01%
SNY	67 Neutral	$117.28B	20.02	7.34%	4.60%	-4.57%	2.96%
BMY	66 Neutral	$94.49B	17.43	31.99%	5.34%	4.62%	―
GSK	59 Neutral	$77.12B	19.64	22.26%	4.54%	4.17%	-29.96%
Sector *	57 Neutral	£4.82B	6.64	-62.36%	5.46%	34.03%	6.31%

Bristol-Myers Squibb Corporate Events

Bristol-Myers Squibb Holds Annual Shareholder Meeting 2025

On May 6, 2025, Bristol-Myers Squibb held its Annual Meeting, where shareholders elected 11 directors to serve until the 2026 meeting. Key decisions included the approval of executive compensation and the ratification of Deloitte & Touche LLP as the independent accounting firm for 2025. However, shareholder proposals on Corporate Financial Sustainability and ceasing DEI efforts were not approved.

Bristol-Myers Squibb Q1 2025 Financial Results Announced

On April 24, 2025, Bristol Myers Squibb announced its financial results for the first quarter of 2025, reporting total revenues of $11.2 billion, a decrease of 6% compared to the previous year. Despite the decline in total revenues, the company’s Growth Portfolio showed significant progress with a 16% increase in revenues, driven by strong performances from products like Opdivo, Breyanzi, Reblozyl, and Camzyos. The company raised its 2025 revenue guidance to a range of $45.8 billion to $46.8 billion, reflecting confidence in its strategic initiatives and pipeline progress.